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Abstract
Background: The orphan GPCR MrgE is one of an extended family of GPCRs that are expressed
in dorsal root ganglia (DRG). Based on these expression patterns it has been suggested that GPCRs
like MrgE may play a role in nociception however, to date, no direct supporting evidence has
emerged. We generated mutant mice lacking MrgE and examined the effects of deletion of this gene
in three pain behavioural models. The effect of MrgE gene deletion on expression of Mrgs and genes
involved in sensory neurone function was also investigated.
Results: The absence of MrgE had no effect on the development of pain responses to a noxious
chemical stimulus or an acute thermal stimulus. However, in contrast, the development but not the
maintenance of neuropathic pain was affected by deletion of MrgE. The expression of Mrg genes
was not significantly affected in the MrgE knockout (KO) mice with the sole exception of MrgF. In
addition, the expression of 77 of 84 genes involved in sensory neuron development and function
was also unaffected by deletion of MrgE. Of the 7 genes affected by MrgE deletion, 4 have previously
been implicated in nociception.
Conclusion: The data suggests that MrgE may play a role in selective pain behavioural responses
in mice.
Background
Mrg-receptors, first described in 2001 [1], constitute a
family of G-protein coupled receptors in which certain
members are expressed in distinct subsets of sensory neu-
rons, known to play a role in nociception, and were acti-
vated by peptides that had previously been functionally
linked to pain. Indirect physiological evidence for a role
for MrgC, in particular, was provided by the demonstra-
tion that peptides known to activate MrgC elicited pain-
like behaviours on administration to rats [2]. Recently it
has been shown that levels of one of these peptides,
Bovine Adrenal Medulla peptide 22, was increased in
superficial laminae of the spinal cord (SC) and in DRG
cells following complete freunds adjuvant induced
inflammation [3]. However the specificity of these pep-
tides for MrgC has not been conclusively demonstrated,
therefore non-MrgC mediated effects cannot be ruled out.
Expression of rat MrgC and MrgA is down regulated in
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DRG following spinal nerve ligation provided additional
evidence that these receptors are somehow functionally
linked to pain [4]. Elegant studies with genetically modi-
fied mice demonstrated that MrgD is uniquely expressed
in primary afferent nerve fibres but pain behavioural phe-
notypes for mice lacking this receptor were not reported
[5]. The MrgD ligand, beta-alanine, inhibited potassium
channel mediated M-current activity in both a recom-
binant cell system and primary DRG neurons suggesting
that activation of MrgD could inhibit the M-current result-
ing in repetitive firing of normally phasic nociceptive neu-
rons leading to pain [6]. Similarly activation of MrgX1
expressed in rat superior cervical ganglion neurons
resulted in M-current inhibition [7].
A functional role for Mrg receptors in other systems could
be assumed from the physiological functions of ligands
known to activate these receptors. MrgX2 is activated by
basic molecules [8] and cortistatin [9], amongst other lig-
ands, and is therefore postulated to have a role in mast cell
degranulation and neuroendocrine function respectively.
Murine MrgA1 and MrgC11 are activated by RF-amide
peptides [10] suggesting that these receptors could be
involved in a variety of neuromodulatory functions attrib-
uted to these peptides [11]. However, as with pain, direct
physiological proof for a role for these receptors in these
systems is lacking.
Study of members of this family is generally hampered by
the lack of specific ligands and/or pharmacological tools.
MrgE is an orphan receptor; however we and others have
demonstrated that this receptor is largely restricted to the
nervous system with greatest expression in SC and DRG
[12]. In the absence of suitable tools we have developed
genetically modified mice lacking MrgE. The phenotype of
MrgE KO mice was studied in a number of assays, with
particular focus on pain behaviours. The effect of deletion
of MrgE on expression of a selection of genes known to be
expressed in sensory neurons, including other Mrgs, was
also investigated.
Results
Generation of MrgE KO mice
MrgE KO mice were generated using a standard homolo-
gous recombination strategy. Southern blot confirmed
homologous recombination had occurred (data not
shown) and a PCR genotyping strategy was used to geno-
type mouse tail DNA samples (see Fig. 1). The genotype of
the MrgE KO animals was confirmed by absence of detect-
able MrgE transcripts in all tissues tested. TaqMan quanti-
tative PCR confirmed the presence of MrgE expression in
DRG, SC and brain from wild-type (WT) mice; whereas
MrgE expression was not detected in homozygote MrgE
KO mice (see Fig. 2).
Behavioural testing of KO and WT mice
KO and WT mice were subjected to a battery of behav-
ioural and biochemical tests. KO mice appeared to be nor-
mal in the majority of tests with some minor differences
noted in blood biochemistry, sexual behaviour and pre-
pulse startle responses. However no overt phenotypic
abnormalities were identified (Data not shown).
The locomotor activity of mice was assessed demonstrat-
ing no difference in the general motor coordination of WT
and KO mice (see Fig. 3).
Intraplantar injection of formalin resulted in a biphasic
nocifensive response in both WT and MrgE KO mice (see
Fig. 4). There was a trend towards reduced nocifensive
behaviours in the KO mice in the first phase of the
response to formalin (see Fig. 4C); however this did not
reach statistical significance. Overall, no significant differ-
ence in the frequency or timing of nocifensive behaviours
between WT and KO mice was detected in either the first
or second phase of the formalin test. Likewise, hotplate
Gene targeting strategy for generation of MrgE KO mice Figure 1
Gene targeting strategy for generation of MrgE KO mice. 
(A) The targeting vector was assembled on the pGT-N28 back-
bone (NEB, Ipswich, MA) and so designed such that a total of 776 
base pairs from within the 930 base pair coding region located in 
exon 2 of the 2 exon MrgE gene (first exon is un-translated) was 
deleted and replaced with a 7,076 base pair IRES-lacZ reporter 
and neomycin resistance cassette. Solid Line: intron 1; boxes 
colored red: exons 1 and 2; box colored blue: coding sequence 
located in exon 2; uncoloured box: IRES-LacZ-NEO cassette 
replacing part of the coding sequence located in exon 2; black tri-
angle: FRT sequence. (B) Genotyping assay was designed to differ-
entiate among wild type (+/+), heterozygote (+/-) or homozygote 
knockout (-/-) MrgE mice and performed using a multiplex PCR 
reaction, with a shared 5' forward primer (5'-GCA GAC ATC 
AGC CAT GAC GT-3') and a 3' reverse primer unique to the tar-
geted allele (#2416, 5'-ATC AGC TTA CCA TGG CCA AGA 
TCC C-3') or to the MrgE locus (5'-ATC TAT CTC TTG GAT 
GTG GCC TG-3'). The WT amplicon is 201 and KO allele 922 
bps.Molecular Pain 2008, 4:2 http://www.molecularpain.com/content/4/1/2
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responses of WT and KO mice were similar (data not
shown)
KO and WT mice developed ipsilateral punctate allodynia
after chronic constriction injury (CCI) of the sciatic nerve.
A statistically significant difference in the rate of develop-
ment of allodynia was demonstrated between WT and
MrgE KO mice (see Fig. 5). The onset of maximal allody-
nia was delayed in the KO in comparison to the WT mice,
with the most significant difference in allodynia noted in
the day 2 to 7 period post surgery. Otherwise, the WT and
MrgE  KO mice maintained a similar level of allodynia
indicated by a paw withdrawal threshold of 0.04 g or less.
The onset of recovery at approximately 100 days post sur-
gery was also similar in both groups.
Gene expression analysis
The expression of Mrg gene family members together with
genes important for sensory neuron function and devel-
opment were examined in various tissues from adult WT
and MrgE KO mice by quantitative RTPCR analysis. In WT
animals, MrgD and E are the most abundant Mrgs in DRG
(see Fig. 2A); whereas MrgE is the most abundant Mrg in
SC and brain with 6000 and 3000 arbitrary copies respec-
tively (see Fig. 2B). There is no statistical difference in the
expression of MrgC11, D, F, G, H and PR4 genes in DRG
of KO and WT mice. However, MrgF is up-regulated 2-fold
(p = 0.0013) in the SC of KO animals (see Fig. 2B).
MrgC11 and D expression was detected at extremely low
levels in brain and SC preparations from some, but not
all, mice while MrgPRa4  or  MrgG  expression was not
Quantitative RTPCR analysis of Mrg expression Figure 2
Quantitative RTPCR analysis of Mrg expression. Quantita-
tive RTPCR analysis of Mrg expression in (A) DRG and (B) SC and 
brain from WT and KO mice. The asterisks indicate that no cop-
ies of MrgE were detected.
Locomotor activity of WT and KO mice Figure 3
Locomotor activity of WT and KO mice. Data is Mean ± SEM of 3–4 mice per group expressed as activity counts per 5 minute bin 
intervals for 1 hour. No significant effect was seen between the groups over the time course.Molecular Pain 2008, 4:2 http://www.molecularpain.com/content/4/1/2
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detected in brain or SC (data not shown). Use of the RT2
PCR profiler array (SuperArray) consisting of genes impli-
cated in patterning, development and/or function of sen-
sory neurones revealed a trend towards reduced
expression of GFR  α-2,  Nav1.7,  Nav1.8, and Runx-1  in
DRG from KO versus WT mice (see Fig. 6) (p = <0.05, p =
*0.07).
The effect of chronic constriction injury of the sciatic
nerve on MrgE gene expression was examined in the rat.
Expression of MrgE in the injured sciatic nerve relative to
the uninjured sciatic nerve was significantly reduced at all
time points post surgery tested (see Fig. 7).
Discussion
MrgE KO and WT mice are indistinguishable in the forma-
lin and hotplate tests implying that MrgE plays no signifi-
cant role in the response to noxious chemical and thermal
stimuli respectively. Dong et al 2001 demonstrated that
MrgD and MrgA1 are expressed in vanniloid receptor-1
(VR1) negative small diameter sensory neurones in the
mouse, indicating that these receptors may be less impor-
tant for the detection of noxious chemical stimuli. At
present the detailed distribution of other Mrgs, including
MrgE, in rodent DRG has not been determined. Taken
together, the KO and distribution data would suggest that
Mrgs, in general, may not be involved in the sensing of
chemically induced pain, although this may not be the
case for higher mammals where distribution of MrgD and
E  in VR1 positive and medium to large diameter neu-
rones, respectively, was detected in DRG [13].
There was a significant difference between WT and KO
mice in the rate they develop an increased hypersensitivity
to the application of von Frey hairs. However the peak
level of allodynia acquired, and maintained, was similar
in both WT and KO mice. The slower rate of onset of allo-
Quantitative RTPCR analysis of DRG expression of genes  involved in sensory neuron function in WT and KO mice Figure 6
Quantitative RTPCR analysis of DRG expression of genes 
involved in sensory neuron function in WT and KO mice. 
RT2 arrays revealed several sensory neurone genes were reduced 
in DRG of the KO relative to WT animals (p = <0.05, p = *0.07). 
Error bars represent standard deviation.
Formalin test of WT and MrgE KO mice Figure 4
Formalin test of WT and MrgE KO mice. (A) The time 
course of development of formalin responses in KO and WT 
mice. (B) The early and late phase of the formalin response in KO 
and WT mice showing a trend towards reduction in early phase 
behaviours in KO mice.
Chronic constriction injury of WT and MrgE KO mice Figure 5
Chronic constriction injury of WT and MrgE KO mice. The 
punctuate allodynia data are expressed as median force (g) 
required to induce a PWT in wild-type (n = 13) and KO (n = 6) 
mice (vertical bars represent the first and third quartiles). ***P < 
0.01, *P < 0.05 unpaired T Test comparing WT and KO mice at 
each time point.Molecular Pain 2008, 4:2 http://www.molecularpain.com/content/4/1/2
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dynia in the KO animals suggests that MrgE plays a role in
the development but not the maintenance of allodynia.
Whether this behavioural effect is directly due to lack of
functional MrgE in adult mice or has arisen due to the
absence of MrgE during the development of the nervous
system in KO animals remains to be seen. In the adult rat
MrgE expression is significantly reduced as early as day 7
post CCI of the sciatic nerve lending further support to the
notion that this gene may be involved in the development
of allodynia. Down regulation of MrgE or a reduction in
cells expressing MrgE may be an essential component of
the temporal processes that affect the development of
allodynia, therefore the complete absence of this gene
deregulates these processes slowing the development of
allodynia in the KO mice.
Emerging data and hypotheses suggest that cellular and
functional plasticity involving neuro-immune interaction
and neuronal long term facilitation, potentiation and
depression in the periphery, at spinal and/or supraspinal
sites may underlie behaviours such as allodynia associ-
ated with persistent pain states (For recent reviews see
[14,15]). Although MrgE is expressed at all tissue levels
known to be involved in pain sensation, the KO data sug-
gests that it has no role in maintaining the long term plas-
tic changes that may underlie neuropathic pain. This
notion is supported by the observation that KO and WT
animals develop the same degree of allodynia.
The small but statistically significant down regulation of
genes known to be involved in sensory neuron function
and development is of interest and may also offer an
explanation. It is tempting to speculate that reduction in
the expression of these genes observed in the DRG of KO
mice may reflect a reduction in the number of neurons
that express these same genes. The loss of these sensory
neurons may result in the observed deficit in the rate of
development of allodynia. Deficits in pain-like behav-
iours have been demonstrated in GFR  α-2  [16]Nav1.7
[17]Nav1.8 [18,19] and Runx-1 [20] KO mice, although
the extent and nature of these behavioural deficits are
much more dramatic than those demonstrated with the
MrgE KOs, possibly because of complete loss of expres-
sion of the genes under study.
The expression of only one Mrg, MrgF was shown to be
altered by MrgE deletion. MrgD gene expression was unaf-
fected by MrgE  deletion although both these receptors
have been shown to functionally associate in a recom-
binant cell system [12]. Although speculative, upregula-
tion of MrgF may compensate for the absence of MrgE
therefore it would be interesting to determine if co-expres-
sion of MrgF had any effect on MrgD function, or if the
pain behavioural phenotype of an MrgF MrgE double KO
would be more profound than that observed with MrgE
KOs.
Conclusion
The data presented in this paper is the first to demonstrate
a role for the orphan GPCR MrgE in pain. The functional
significance of MrgE deletion on pain will require exten-
sion of these studies to detailed molecular and immuno-
histochemical analysis of the KO mice, and further
analysis of the effects of MrgE gene deletion on other pain
endpoints and in other pain models.
Methods
Generation of MrgE KO mice
MrgE targeted ES clone was obtained from Deltagen (San
Carlos, CA.). A genomic fragment containing the MrgE
gene was isolated from a mouse genomic phage library.
The targeting vector was assembled on the pGT-N28 back-
bone (NEB, Ipswich, MA) and so designed that a total of
776 bps from within the 930 base pair coding region
located in exon 2 of MrgE gene (first exon is un-trans-
lated) was deleted and replaced with a 7,076 bp IRES-lacZ
reporter and neomycin resistance cassette (IRES-LacZ-
NEO) (see Fig. 1A). The targeting vector was linearized
and electroporated into the E14 (129/Ola) mouse embry-
onic stem (ES) cells. ES cells were then cultured in the
presence of the antibiotic G418/geneticin, and surviving
colonies carrying the homologously integrated neo DNA
were identified by PCR amplification, retrieving a 6.5 kb
fragment, using a neo-specific reverse primer (#2416, 5'-
ATCAGCTTACCATGGCCAAGATCCC-3') paired with a
forward primer located 5' to the 5' homology arm
(#71732, 5'-GACATCTCCCTAGTCCAGACGACTC-3').
Successful homologous recombination at the 3' end was
also confirmed using a neo-specific forward primer
Quantitative RTPCR analysis of MrgE expression post CCI in  the rat Figure 7
Quantitative RTPCR analysis of MrgE expression post 
CCI in the rat. MrgE expression was reduced in ipsi-versus con-
tralateral sciatic nerve from rats 7, 14 and 21 days post CCI sur-
gery (n = 6 per time point) (Error bars represent standard 
deviation P < 0.01). Expression of MrgE in ipsi- and contralateral 
sciatic nerve from naïve animals was unchanged (data not shown).Molecular Pain 2008, 4:2 http://www.molecularpain.com/content/4/1/2
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(#1431, 5'-ACGTACTCGGATGGAAGCCGGTCTT-3')
paired with a reverse primer located 3' to the 3' homology
arm (#71738: 5'-CCTCCTTCTCTCTCCACGTGTTCCT-3'),
retrieving a 7.0 kb fragment. Colonies that gave rise to the
correct PCR products were confirmed by Southern blot
analysis and presence of a single neo cassette in the
genome was also confirmed by Southern blot analysis
using a neo gene fragment as a probe (data not shown).
Targeted ES cells were injected into C57Bl/6J blastocysts
and male chimeric mice were generated and bred with
C57Bl/6J female mice to produce F1 heterozygous off-
spring. F1 germline mice were then bred to C57BL/6J wild
type mice to expand the colony and heterozygote mice
were interbred to produce the study population mice. All
phenotypic analysis was performed on a hybrid C57Bl/6J/
129 background. Genotyping to detect wild type, hetero-
zygote and homozygote mice was performed using a mul-
tiplex PCR reaction, with a shared 5' forward primer (5'-
GCA GAC ATC AGC CAT GAC GT-3') and a 3' reverse
primer unique to the targeted allele (#2416, 5'-ATC AGC
TTA CCA TGG CCA AGA TCC C-3') or to the MrgE locus
(5'-ATC TAT CTC TTG GAT GTG GCC TG-3'). The WT
product is 201 and mutant allele 922 bps (see Fig. 1B).
Behavioural testing of KO and WT mice
All animals were handled in accordance with Pfizer policy
on animal welfare and with regional government legisla-
tion on the use of animals in research.
The spontaneous locomotor activity of the mice was
measured by placing the animals in a novel environment
which is monitored for 1 hr in a 35 × 20 cm perspex cham-
ber equipped with a series of two photocells located at 1
and 10 cm above the floor. Each animal was placed in the
centre of the cage and total locomotor activity (ambula-
tion and rearing) was monitored every 5 min and
recorded as activity counts as the beams were broken.
Activity data was captured on computer. Mice were ran-
domly placed in the photo beam equipped cages.
Acute pain responses were assessed using the formalin
and hotplate tests. Mice were subjected to the formalin
test as follows. Homozygote KO mice and WT littermates
were habituated to perspex boxes for 15 minutes before
20 ul of 5% formalin was administered into the plantar
surface of the right hind paw. Nocifensive behaviour was
assessed by measuring the time spent licking and biting in
5-minute bins for 45 minutes following formalin injec-
tion.
Neuropathic pain behaviours in mice were assessed fol-
lowing CCI of the right sciatic nerve based on previously
described methods [21]. Mice were placed in an anaes-
thetic chamber and anaesthetised with a 2% isofluorane
O2 mixture. The right hind thigh was shaved and swabbed
with 1% iodine. Animals were then transferred to a home-
othermic blanket for the duration of the procedure and
anaesthesia maintained during surgery via a nose cone.
The skin was cut along the line of the thighbone and the
common sciatic nerve was exposed at the middle of the
thigh by blunt dissection through biceps femoris. Three
ligatures (4-0 silk) were tied loosely around the nerve, the
wound was closed and the animals allowed to recover.
Following surgery the development of static allodynia was
monitored regularly over a period of 4 weeks. Static allo-
dynia was evaluated by application of von Frey hairs
(Stoelting, Wood Dale, Illinois, U.S.A) in ascending order
of force (0.008, 0.02, 0.04, 0.07, 0.16, 0.4, 0.6, 1, 1.4, 2, 4
grams) to the plantar surface of hind paws. Each von Frey
hair was applied to the paw for a maximum of 6 seconds,
or until a withdrawal response occurred. Once a with-
drawal response was established, the paw was re-tested,
starting with the filament below. The lowest amount of
force required to elicit a response was recorded as paw
withdrawal threshold (PWT) in grams. Static allodynia
was defined as present if animals responded to a force
equal to or less than, 0.04 g, which is innocuous in nor-
mal mice. CCI of the rat sciatic nerve was performed as
described previously [21].
Gene expression analysis
Mrg  family members and genes important for sensory
neuron development and function were quantified in var-
ious tissues from adult WT and MrgE KO mice by quanti-
tative RTPCR analysis. DRG, SC and brain tissues (n = 6)
were harvested from KO and WT mice, stored in RNAlater
(Ambion) at -20°C. Tissues were mechanically homoge-
nised using Powergen 125 (Fisher) in 600 ul Buffer RLT
(Qiagen) containing β-Mercaptoethanol (10 ul/ml RLT).
SCs and brains were homogenised whole in larger vol-
umes (1.2 ml and 6 ml) accordingly and RNA was
extracted as per the RNeasy tissue protocol (Qiagen) with
on column DNaseI treatment. Brains and SCs were also
treated with Amplification Grade DNaseI (Invitrogen) in
accordance with the manufacturer's instructions. RNA was
reverse transcribed using the GeneAmp RNA PCR kit
(Applied Biosystems) and 15 ng/well equivalent of cDNA
used in quantitative PCR TaqMan® to determine gene
expression levels of MrgC11, D, E and G using custom oli-
gos (Sigma) and MrgF,  H  and  PR4  using Assays on
Demand™ (Applied Biosystems). Arbitrary copy number
(ACN) was calculated using the formula ACN = 10(12-
(0.3xCt)). Multiple gene profiling of the DRGs was per-
formed using 1 ng cDNA per well on a custom RT2 PCR
profiler array (SuperArray) and the data analysed using
Spotfire Decision site 8.1. The ACN +/-standard deviation
was calculated as described. Sciatic nerve was harvested
from rats 7, 14 and 21 days post CCI. RNA was isolated
from sciatic nerve ipsilateral and contralateral to thePublish with BioMed Central    and   every 
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injured nerve. cDNA was synthesized from isolated sciatic
nerve RNA as described for murine RNA. 25 ng/well of
cDNA equivalent was used as template in rat MrgE specific
TaqMan assays and the data generated analysed using a
ΔΔCt method (Applied Biosystems). Ipsilateral versus
contralateral levels of MrgE were compared for each time
point post surgery and expressed as relative copy number.
The sequences of all primers and probes used in this study
are available on request.
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